Sunil Bharwani, MD
Family Medicine · Ocala, FLNPI 1699967877
Payments from drug & device makers
Across 222 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$608
- GSK$503
- Novo Nordisk$404
- Lilly USA, LLC$325
- Takeda Pharmaceuticals U.S.A., Inc.$212
- AstraZeneca$194
- plus $1K from 27 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$3,61599%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $608 |
| GSK | 29 | $503 |
| Novo Nordisk | 25 | $404 |
| Lilly USA, LLC | 21 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $212 |
| AstraZeneca | 14 | $194 |
| Amgen | 11 | $180 |
| Novartis | 6 | $113 |
| Boehringer Ingelheim | 7 | $101 |
| Organogenesis Inc. | 1 | $100 |
| Merck | 7 | $94 |
| Otsuka America Pharmaceutical, Inc. | 6 | $92 |
| Teva Pharmaceuticals USA, Inc. | 6 | $80 |
| Amarin Pharma, Inc. | 5 | $76 |
| Johnson & Johnson | 4 | $60 |
| Pfizer | 3 | $56 |
| Astellas Pharma US Inc | 3 | $55 |
| Abbott | 4 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Bayer | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Boston Scientific | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apligraf$100
- Dermagraft$100
- Puraply/Affinity/NuTech$100
How this compares
$3,645 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $48,151 |
| OzempicSemaglutide | 34 | $40,551 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $36,938 |
| JardianceEmpagliflozin | 22 | $32,377 |
| TrulicityDulaglutide | 14 | $28,724 |
| JanuviaSitagliptin Phosphate | 17 | $27,954 |
| Repatha SureclickEvolocumab | 21 | $19,051 |
| VraylarCariprazine Hcl | 13 | $18,909 |
| XareltoRivaroxaban | 23 | $18,604 |
| EntrestoSacubitril/Valsartan | 17 | $14,994 |
| MyrbetriqMirabegron | 18 | $13,552 |
| TrulancePlecanatide | 12 | $10,150 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,584 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $4,602 |
| Levothyroxine Sodium | 143 | $2,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $56 | $49,56463 claims |
| Novo NordiskOzempic | $404 | $40,55134 claims |
| GSKTrelegy Ellipta | $503 | $36,93839 claims |
| Boehringer IngelheimJardiance | $101 | $32,37722 claims |
| Lilly USA, LLCTrulicity | $325 | $28,72414 claims |
| MerckJanuvia | $94 | $27,95417 claims |
| AbbVieVraylar, Synthroid | $608 | $20,31532 claims |
| Johnson & JohnsonXarelto | $60 | $18,60423 claims |
| NovartisEntresto | $113 | $14,99417 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $13,55218 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $13 | $10,15012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- John NardandreaOcala$30.8M
- David OliverOcala$4.5M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.